Postremission therapy with two different dose regimens of cytarabine in adults with acute myelogenous leukemia

Shpilberg, Ofer; Haddad, Nuhad; Sofer, Orit; Raanani, Pia; Berkowicz, Miriam; Chetrit, Angela; Carter, Anna; Ramot, Bracha; Tatarski, I.; Ben‐Bassat, Isaac

doi:10.1016/0145-2126(95)00082-8

Cited by 2 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors attributed the VOD to the dose escalation of cyclophosphamide (2.2 g/m 2 ). In the treatment of acute myeloid leukemia some form of post-remission therapy is necessary to prolong remission duration and overall survival and in patients younger than 60 years, consolidation chemotherapy regimens containing high-dose cytosine arabinoside provide better results than intermediate-dose cytarabine [16]. We therefore treated the patient first with intermediate-dose cytosine arabinoside consolidation course, and when no significant liver toxicity appeared we continued with 2 courses of high-dose cytosine arabinoside.…”

Section: Discussionmentioning

confidence: 99%

Clinical severe hepatic venoocclusive disease during induction treatment of acute monoblastic leukemia managed with defibrotide

et al. 2002

View full text Add to dashboard Cite

Hepatic venoocclusive disease (VOD) is the most common complication of cytoreductive therapy used for stem cell transplantation, but it is rarely encountered during induction treatment of acute leukemia. We describe a patient in whom severe clinical VOD developed shortly after induction treatment for acute monoblastic leukemia. Administration of intravenous defibrotide for 19 days induced complete resolution of the VOD. Further consolidation treatment was resumed including high-dose cytosine arabinoside without further complications. Am.

show abstract

Section: Discussionmentioning

confidence: 99%